Search research articles
Contact Us
Filters
Showing results (321-330 of 378) with videos related to
Page
of 38
Sort By:
Lancet (London, England)
|
May 19, 2009
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial
Paul Ellis, Peter Barrett-Lee, Lindsay Johnson, et al.
The Lancet. Oncology
|
August 2, 2013
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial
Stephen Rd Johnston, Lucy S Kilburn, Paul Ellis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 2025
The Prognostic and Predictive Impact of ctDNA Levels in Patients with Advanced Breast Cancer Enrolled on the plasmaMATCH Trial
Iseult M Browne, Javier Pascual, Rosalind J Cutts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 4, 2017
Long-Term Follow-Up of the Intergroup Exemestane Study
James P Morden, Isabel Alvarez, Gianfilippo Bertelli, et al.
Plos One
|
September 26, 2014
Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure
Sumi Biswas, Prateek Choudhary, Sean C Elias, et al.
The Lancet. Oncology
|
June 11, 2017
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial
David Cameron, James P Morden, Peter Canney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 11, 2023
Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer
Pamela J Goodwin, Bingshu E Chen, Karen A Gelmon, et al.
Breast Cancer Research and Treatment
|
November 15, 2014
NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer
C Palmieri, S Cleator, L S Kilburn, et al.
Scientific Reports
|
February 23, 2018
Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP
Carly M Bliss, Georgina Bowyer, Nicholas A Anagnostou, et al.
Breast Cancer Research : BCR
|
April 26, 2026
Genomic and spatial analysis of local recurrences following risk-adapted breast radiotherapy in the IMPORT trials
Sara V Lightowlers, Maria Roman-Escorza, Ceilidh Welsh, et al.
Page
of 38
Search research articles
Search
Showing results (321-330 of 378) with videos related to
Sort By:
Page
of 38
Lancet (London, England)
|
May 19, 2009
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial
Paul Ellis, Peter Barrett-Lee, Lindsay Johnson, et al.
The Lancet. Oncology
|
August 2, 2013
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial
Stephen Rd Johnston, Lucy S Kilburn, Paul Ellis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 2025
The Prognostic and Predictive Impact of ctDNA Levels in Patients with Advanced Breast Cancer Enrolled on the plasmaMATCH Trial
Iseult M Browne, Javier Pascual, Rosalind J Cutts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 4, 2017
Long-Term Follow-Up of the Intergroup Exemestane Study
James P Morden, Isabel Alvarez, Gianfilippo Bertelli, et al.
Plos One
|
September 26, 2014
Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure
Sumi Biswas, Prateek Choudhary, Sean C Elias, et al.
The Lancet. Oncology
|
June 11, 2017
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial
David Cameron, James P Morden, Peter Canney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 11, 2023
Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer
Pamela J Goodwin, Bingshu E Chen, Karen A Gelmon, et al.
Breast Cancer Research and Treatment
|
November 15, 2014
NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer
C Palmieri, S Cleator, L S Kilburn, et al.
Scientific Reports
|
February 23, 2018
Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP
Carly M Bliss, Georgina Bowyer, Nicholas A Anagnostou, et al.
Breast Cancer Research : BCR
|
April 26, 2026
Genomic and spatial analysis of local recurrences following risk-adapted breast radiotherapy in the IMPORT trials
Sara V Lightowlers, Maria Roman-Escorza, Ceilidh Welsh, et al.
Page
of 38